“Targeting IL23p19 Using Risankizumab for the Management of Moderate-to-Severely Active Crohn’s Disease: The Next Frontier?”. 2023. Canadian IBD Today 1 (S05): 2–7. https://doi.org/10.58931/cibdt.2023.1S0510.